We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Akkermansia muciniphila
A next-generation gut bacterium studied mainly for metabolic health. A small proof-of-concept RCT hinted at insulin-sensitivity benefits, but a larger 2025 trial was null overall — improvement appeared only in people who started with low Akkermansia levels. Promising but early, with a thin and inconsistent human evidence base.
What the evidence says
Most Akkermansia studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2019–2026 with a typical study size of 58 participants.
Based on 34 studies · 1 meta-analysis · 7 RCTs · 374 total participants
Confidence
Moderate confidenceBy outcome
Only three small RCTs: an early proof-of-concept hinted at insulin-sensitivity benefit, but the larger 2025 trial (n=58) was null overall — improvement appeared only in low-baseline-Akkermansia subjects.
22 trials ongoing or recruiting · 14 completed on ClinicalTrials.gov
Registered trials show research momentum for Akkermansia, not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Sep 2026
Akkermansia muciniphila is a mucin-degrading gut bacterium associated with metabolic health; lower levels correlate with obesity and insulin resistance.
An early proof-of-concept RCT suggested that supplementing the PASTEURIZED form improved insulin sensitivity and some metabolic markers in overweight/insulin-resistant adults — but this was a small, exploratory study.
A larger 2025 randomized trial (n=58) found no overall between-group metabolic benefit; improvement was confined to a subgroup that started with low baseline Akkermansia. A separate RCT reported a muscle-strength signal.
Most of the supporting evidence remains preclinical and mechanistic, and the human data are thin and inconsistent — this is a genuinely interesting 'next-generation' probiotic, but its benefits are not yet established.
Strengthens the gut mucus layer and barrier integrity, reducing metabolic endotoxemia.
Proposed to improve insulin sensitivity, though human trial results have been inconsistent.
How Akkermansia works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Check which form you have. The standard product — and the one that outperformed in the key trial — is PASTEURIZED A. muciniphila, which is non-viable: it cannot colonise or translocate, so the bloodstream-infection route documented for live probiotics does not apply. A live form is sold as an alternative, and for that the usual live-organism caution applies with no safety data in immunosuppression to offset it. Discuss with a clinician either way.
Not studied — avoid.
May add to glucose-lowering — monitor.
Tip: Usually transient
Akkermansia has an evidence score of 4.2/10 — emerging evidence based on 25 indexed studies. A next-generation gut bacterium studied mainly for metabolic health. A small proof-of-concept RCT hinted at insulin-sensitivity benefits, but a larger 2025 trial was null overall — improvement appeared only in people who started with low Akkermansia levels. Promising but early, with a thin and inconsistent human evidence base. Representative study: PMID 31263284.
The commonly studied dose of Akkermansia is Pasteurized A. muciniphila ~10^10 cells daily (per studied products). Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Timing is flexible for Akkermansia — consistent daily use matters more than the time of day. Once daily per product labeling; the pasteurized form was used in the key trials.
Akkermansia is generally well-tolerated and considered safe for most healthy adults at recommended doses. Reported side effects are uncommon and include mild GI changes. Use caution if any of these apply to you: Severe immunocompromise — applies to the LIVE form; the standard pasteurized product is non-viable and carries no infection risk by this route; Pregnancy/breastfeeding (not studied).
Berberine
Likely helpsActivates AMPK to regulate blood sugar, improve insulin sensitivity, and support lipid metabolism — comparable to metformin in some trials.
Gymnema Sylvestre
Mostly mechanism / observationalAn Ayurvedic herb studied for supporting blood-sugar control and for temporarily blunting sweet taste and sugar cravings.
Magnesium
Likely helpsSupports 300+ enzymatic reactions — critical for sleep, stress response, muscle function, and cognitive health.
Green Tea Extract
Likely helpsConcentrated catechins from green tea that support metabolism, fat oxidation, brain health, and antioxidant defense.
Explore: Best supplements for Vitality & Longevity
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 34 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research